Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients
Authors
Keywords
-
Journal
Cardiovascular Toxicology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-29
DOI
10.1007/s12012-019-09556-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cardiotoxicity of anthracycline therapy: current perspectives
- (2016) Mihaela Valcovici et al. Archives of Medical Science
- Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials
- (2016) Katarzyna Rygiel INDIAN JOURNAL OF PHARMACOLOGY
- Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs
- (2016) Robin K. Kuriakose et al. Oxidative Medicine and Cellular Longevity
- Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma
- (2014) Sebastian Szmit et al. Journal of the American Society of Hypertension
- 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension
- (2013) Giuseppe Mancia et al. BLOOD PRESSURE
- Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats
- (2013) Leslie C. Sharkey et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
- (2012) G. Curigliano et al. ANNALS OF ONCOLOGY
- Anthracycline cardiotoxicity
- (2011) Pierantonio Menna et al. Expert Opinion On Drug Safety
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) S. Aebi et al. ANNALS OF ONCOLOGY
- Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2010) Thomas Eschenhagen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
- (2009) Adriana Albini et al. JNCI-Journal of the National Cancer Institute
- Continuous Electrocardiogram Reveals Differences in the Short-Term Cardiotoxic Response of Wistar-Kyoto and Spontaneously Hypertensive Rats to Doxorubicin
- (2009) Mehdi S. Hazari et al. TOXICOLOGICAL SCIENCES
- Anthracycline Cardiotoxicity: From Bench to Bedside
- (2008) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma
- (2008) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started